Brexanolone: A Review of the Novel Drug Injection for Postpartum Depression Public Deposited
Downloadable ContentDownload PDF
MLA citation style. 2020. https://mushare.marian.edu/concern/generic_works/b1903758-cb51-42a8-9203-8707af4f77fe Brexanolone: A Review of the Novel Drug Injection for Postpartum Depression.
APA citation style(2020). Brexanolone: A Review of the Novel Drug Injection for Postpartum Depression. https://mushare.marian.edu/concern/generic_works/b1903758-cb51-42a8-9203-8707af4f77fe
Chicago citation styleBrexanolone: A Review of the Novel Drug Injection for Postpartum Depression. 2020. https://mushare.marian.edu/concern/generic_works/b1903758-cb51-42a8-9203-8707af4f77fe
Note: These citations are programmatically generated and may be incomplete.
Brexanolone (ZULRESSO ™) is a novel approach to treat postpartum depression in adult women as a neuroactive steroid similar in chemical composition to the hormone allopregnanolone. It was approved for use in adult women suffering from postpartum depression by the FDA in March 2019, with emphasis on its potential use in patients who are unresponsive to mainstay interventions. Brexanolone is the only drug currently on the market approved to treat PPD, use of Brexanolone requires patients to be enrolled in the REMS (Risk Evaluation and Mitigation Strategies) ZULRESSO™ program necessitating a 60-hour period of intravenous administration and close monitoring. The pharmacogenomics of this drug have yet to be studied but could potentially aide in determining if Brexanolone administration is an appropriate therapy for a patient. Additional clinical studies with larger sample sizes are necessary in order to evaluate the use of Brexanolone in women with PPD.